Cost effectiveness of topiramate in the prevention of migraines in the United States: An update

Managed Care Interface

Volumn 19, Issue 12, 2006, Pages 31-38

  Brown, Jeffrey S ^a   Rupnow, Marcia F T ^b   Neumann, Peter ^c   Friedman, Mark ^a   Menzin, Joseph ^a  

^a Boston Health Economics Inc   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

^c TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

SUMATRIPTAN; TOPIRAMATE; TRIPTAN DERIVATIVE;

ANALYTIC METHOD; ARTICLE; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECISION ANALYTIC MODEL; DECISION TREE; DISABILITY; DISEASE DURATION; DRUG EFFICACY; DRUG RESPONSE; HUMAN; INCOME; MIGRAINE; MONEY; OUTCOME ASSESSMENT; PROBABILITY; UNITED STATES;

COST-BENEFIT ANALYSIS; FRUCTOSE; HUMANS; MIGRAINE DISORDERS; NEUROPROTECTIVE AGENTS; UNITED STATES;

EID: 33846410246     PISSN: 10965645     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Silberstein S, Diamond S, Loder E, et al: Prevalence of migraine sufferers who are candidates for preventive therapy: Results from the American Migraine Prevalence and Prevention study. Headache 2005;45:770-771.
2. Lipton RB, Stewart WF, Diamond S, et al: Prevalence and burden of migraine in the United States: Data from the American Migraine Study II. Headache 2001;41:646-657.
3. Hu XH, Markson LE, Lipton RB, et al: Burden of migraine in the United States: Disability and economic costs. Arch Intern Med 1999; 159:813-818.
4. Clouse JC, Osterhaus JT: Healthcare resource use and costs associated with migraine in a managed healthcare setting. Ann Pharmacother 1994;28:659-664.
5. Meskunas CA, Tepper SJ, Rapoport AM, et al: Medications associated with probable medication overuse headache reported in a tertiary care headache center over a 15-year period. Headache 2006;46:766-772.
6. Migraine Update. National Institute of Neurological Disorders and Stroke-National Institutes of Health (www.ninds.nih.gov/ disorders/migraine/ migraine.htm), December 1, 2005.
7. Silberstein SD, Winner PK, Chmiel JJ: Migraine preventive medication reduces resource utilization. Headache 2003;43:171-178.
8. Ramadan NM, Silberstein SD, Freitag FG, et al: Evidence-based guidelines for migraine headache in the primary care setting: Pharmacologic management for prevention of migraine. 2000. American Academy of Neurology (www.aan.com/ professionals/practice/ pdfs/gl0090.pdf), December 2, 2005.
9. Snow V, Weiss K, Wall EM, et al: Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann Intern Med 2002; 137: 840-849.
10. Brandes JL, Saper JR, Diamond M, et al: Topiramate for migraine prevention: A randomized controlled trial. JAMA 2004;291: 965-973.
11. Silberstein SD, Neto W, Schmitt J, et al: Topiramate in migraine prevention: Results of a large controlled trial. Arch Neurol 2004; 61:490-495.
12. Diener HC, Tfelt-Hansen P, Dahlof C, et al: Topiramate in migraine prophylaxis: Results from a placebo-controlled trial with propranolol as an active control. J Neurol 2004; 251:943-950.
13. Diamond M, Dahlöf C, Papadopoulos G, et al: Topiramate improves health-related quality of life when used to prevent migraine. Headache 2005;45:1023-1030.
14. Silberstein SD, Loder E, Forde G, et al: The impact of migraine on daily activities: Effect of topiramate compared with placebo. Curr Med Res Opin 2006;22:1021-1029.
15. Kaniecki R, Lucas S: Treatment of Primary Headache: Preventive Treatment of Migraine, Standards of Care for Headache Diagnosis and Treatment. Chicago, National Headache Foundation, 2004; 40-52.
16. Brown JS, Papadoupoulos G, Neumann PJ, et al: Cost effectiveness of topiramate in migraine prevention: Results from a pharmacoeconomic model of topiramate treatment. Headache 2005;45:1012-1022.
17. Headache Classification Subcommittee of the International Headache Society: The international classification of headache disorders. Ed. 2. Cephalalgia 2004;24:9-160.
18. Forde G, Lake AE III, Jacobs D, et al: The efficacy of topiramate in migraine prevention: Analyses of pooled data from two, 26-week, placebo-controlled, double-blind topiramate trials (poster). Presented at the 46th annual meeting of the American Headache Society. Vancouver, Canada, June 10-13, 2004.
19. Adelman J, Lainez JM, Jacobs D, et al: Safety assessment of topiramate in migraine prevention: Pooled results from over 1,500 patients (poster). Presented at the 56th annual meeting of the American Academy of Neurology. San Francisco, April 24-May 1, 2004.
20. Dodick D, Hulihan J, Wu S: Do migraine preventive medications enhance the efficacy of triptans? Analyses from topiramate migraine trials. Presented at the 15th Migraine Trust International Symposium, London, September 20-23, 2004.
21. Lipton RB, Scher AI, Steiner TJ, et al: Patterns of health care utilization for migraine in England and in the United States. Neurology 2003;60:441-448.
22. Caro G, Getsios D, Caro JJ, et al: Sumatriptan: Economic evidence for its use in the treatment of migraine, the Canadian comparative economic analysis. Cephalalgia 2001; 21:12-19.
23. RedBook Drug Products and Pricing Select Database. Greenwood Village, CO, Thomson Micromedex, January 2005.
24. The online resource for drug pricing information. AnalySource, Online, DMD America (www.analysource.com), June 2005.
25. Median weekly earnings for women age 25-54. U.S. Department of Labor, Bureau of Labor Statistics, last quarter, 2004 (www.bls. gov/ppi/ppinaics.htm).
26. Caro JJ, Getsios D, Raggio G, et al: Treatment of migraine in Canada with naratriptan: A cost-effectiveness analysis. Headache 2001;41:456-464.